Vatalanib in advanced colorectal cancer: Two studies with identical results

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 1938-1940

  Sobrero, Alberto F ^a   Bruzzi, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL PRODUCT; CAPECITABINE; CEDIRANIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; PANITUMUMAB; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR INHIBITOR; VATALANIB;

ADD ON THERAPY; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CARCINOGENESIS; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HAZARD RATIO; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; PHTHALAZINES; PYRIDINES; TREATMENT OUTCOME;

EID: 79956334138     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.2429     Document Type: Editorial

References (18)

1. Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebocontrolled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
2. Van Cutsem E, Bajetta E, Valle J, et al: Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004-2010, 2011
3. Goffin J, Baral S, Tu D, et al: Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res 11:5928-5934, 2005 (Pubitemid 41170322)
4. El-Maraghi RH, Eisenhauer EA: Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26:1346-1354, 2008
5. Thomas AL, Morgan B, Horsfield MA, et al: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. Clin Oncol 23:4162-4171, 2005 (Pubitemid 46211322)
6. Hoff PM, Hochhaus A, Pestalozzi BC, et al: Cediranib + FOLFOX/XELOX versus placebo+ FOLFOX/XELOX in patients with previously untreated metastatic colorectal cancer: A randomized, double blind, phase III study (HORIZON II). Ann Oncol 21:9, 2010 (suppl 8, abstr LBA 19)
7. Maughan T, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based combination chemotherapy in patients with KRAS wild-type advanced colorectal cancer: A randomized superiority trial (MRC COIN). Eur J Cancer 7:10, 2009 (suppl 6)
8. Tveit K, Guren T, Glimelius B, et al: Randomized phase III study of 5-fluorouracil /folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. Ann Oncol 21:9, 2010 (suppl 8, abstr LBA 20)
9. Siena S, Cassidy J, Tabernero J, et al: Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. ASCO Gastrointestinal Symposium, 2010 (abstr 283)
10. Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
11. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
12. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572, 2009
13. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680, 2009
14. Schmoll H, Cunningham D, Sobrero A, et al: MFOLFOX 6 + cediranib vs MFOLFOX 6 + bevacizumab in previously untreated metastatic colorectal cancer: A randomized, double blind, phase II/III study (HORIZON III). Ann Oncol 21:189, 2010, (suppl 8, abstr 5800)
15. Tabernero J, Aranda E, Gomez A, et al Phase III study of first line XELOX plus bevacizumab for 6 cycles followed by XELOX plus bev or single agent bev as maintenance therapy in patients with metastatic colorectal cancer: The MACRO trial. J Clin Oncol 28:261s, 2010 (abstr 3501)
16. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232-239, 2009
17. Wolmark N, Yothers G, O'Connell MJ, et al: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 27:6s, 2009 (suppl 18, abstr LBA4)
18. Kopetz S, Chang GJ, Overman MJ, et al: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677-3683, 2009